Blood Thinner Cost on Medicare in 2026: Eliquis vs Xarelto vs Warfarin

Eliquis (apixaban), Xarelto (rivaroxaban), and warfarin (Coumadin, Jantoven) are the three most commonly prescribed anticoagulants for Medicare beneficiaries who need stroke prevention in atrial fibrillation or treatment of deep vein thrombosis and pulmonary embolism. Eliquis and Xarelto belong to a newer drug class called direct oral anticoagulants (DOACs) that block factor Xa in the clotting cascade and do not require routine blood testing. Warfarin is a vitamin K antagonist that has been on the market since 1954 and requires regular INR (International Normalized Ratio) blood testing to keep dosing in a safe range. That clinical difference translates into very different 2026 costs and Medicare billing patterns, which is the focus of this comparison.

Medicare's Inflation Reduction Act drug price negotiation program changed the math for two of these three drugs starting January 1, 2026. CMS selected Eliquis and Xarelto for its first round of negotiated Maximum Fair Prices, announced in August 2024, cutting Eliquis to $231 per month from a list price of $521 and Xarelto to $197 per month from a list price of $517. Warfarin was never eligible for IRA negotiation because it has been a fully generic, off-patent drug for decades; the statute only allows CMS to select drugs that still face brand-only competition. That distinction means warfarin's 2026 cost is set by ordinary Part D generic-tier pricing rather than a federally negotiated ceiling, and it has stayed in the $4 to $15 per month range for years.

Patients switching between these three blood thinners for cost reasons should talk to their prescriber first, since Eliquis, Xarelto, and warfarin have different dosing schedules, different reversal agents in a bleeding emergency (andexanet alfa for Eliquis and Xarelto; vitamin K and prothrombin complex concentrate for warfarin), and very different monitoring requirements. None of the three is a biologic, so no biosimilar exists or is expected for any of them; the biosimilar approval pathway only applies to large-molecule drugs. For single-drug detail beyond this Medicare-focused comparison, see the dedicated pages for Eliquis cost and Xarelto cost.

What Blood Thinner Cost on Medicare Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same blood thinner cost on medicare can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Hospitals rarely bill any of these three blood thinners as a standalone pharmacy line item when the drug is given during an inpatient stay. Eliquis, Xarelto, and warfarin doses given while admitted are bundled into the Diagnosis-Related Group (DRG) payment Medicare pays the hospital for that admission, regardless of which specific anticoagulant was used. Private insurers negotiate their own bundled inpatient rates separately from any single drug's retail price. Uninsured patients face the hospital's chargemaster rate for the bundled stay, which can run several times what an outpatient 30-day supply of the same drug would cost at a retail pharmacy.

Medicare Part A stops paying for the blood thinner the moment a patient is discharged, and coverage shifts entirely to Medicare Part D for the outpatient prescription. That transition is where the 2026 IRA Maximum Fair Price for Eliquis ($231/month) and Xarelto ($197/month) kicks in, along with the generic Tier 1 copay for warfarin. Patients discharged on warfarin also need a follow-up INR blood draw within days, which is billed to Medicare Part B separately from the Part A hospital stay and Part D prescription. Anyone leaving the hospital on a new anticoagulant without an active Part D plan or a scheduled INR follow-up should call 1-800-MEDICARE before the first fill.

Warfarin's total cost of ownership includes more than the pharmacy price. Medicare covers routine PT/INR laboratory testing at 100% under Part B with no deductible or coinsurance, but patients still need transportation to a lab or clinic every one to four weeks, or must qualify for a home INR monitor under Medicare's National Coverage Determination 190.11, which applies to patients with mechanical heart valves, chronic atrial fibrillation, or venous thromboembolism after at least three months of warfarin therapy. Eliquis and Xarelto patients skip this recurring visit entirely, which is the real-world trade-off behind warfarin's lower sticker price and is why prescribers weigh convenience alongside cost when choosing an anticoagulant for a Medicare beneficiary.

Patient Assistance Programs

Bristol Myers Squibb and Janssen each run a separate patient assistance program for Eliquis and Xarelto, and the income thresholds differ. Warfarin does not need an income-gated patient assistance program because the generic cash price is already $4 to $15 per month at most pharmacies. If you have no insurance and take Eliquis or Xarelto, apply directly to the manufacturer of your specific drug; there is no combined blood-thinner assistance program covering all three.

Medicare Part D

Medicare Part D treats these three blood thinners very differently in 2026. Eliquis and Xarelto are subject to the IRA Maximum Fair Price of $231 and $197 per month respectively, applied at any network pharmacy regardless of which specific plan you carry. Warfarin has no negotiated price because it needs none; nearly every Part D plan places generic warfarin on Tier 1, the lowest cost-sharing tier, typically $0 to $5 per fill. All out-of-pocket spending on any of the three drugs counts toward the same 2026 Part D annual out-of-pocket cap of $2,100; once you hit that cap across all your Part D drugs combined, you pay $0 for the rest of the calendar year.

Extra Help (the Part D Low Income Subsidy) reduces cost-sharing further for Medicare beneficiaries with limited income and resources. In 2026, Extra Help enrollees pay $12.65 per fill for a brand-name drug like Eliquis or Xarelto, and a small or $0 copay for generic warfarin. Extra Help is generally available to beneficiaries with income at or below 150% of the Federal Poverty Level. Apply through the Social Security Administration at 1-800-772-1213 or at ssa.gov, and separately, if you are on warfarin, ask your Part B plan whether you qualify for a home INR monitor under Medicare's coverage rules, since that can eliminate repeat lab visits without changing your prescription.

Common Blood Thinner Cost on Medicare Billing Errors

All three blood thinners are self-administered oral tablets billed through Part D or a commercial pharmacy benefit rather than Part B, so most billing problems appear on pharmacy claims or Explanation of Benefits statements rather than hospital bills. Watch for these issues:

• Pharmacy charges more than the $231 Eliquis or $197 Xarelto IRA Maximum Fair Price for a Medicare Part D fill in 2026, which violates federal law; ask your plan's member services to reprocess the claim.
• Generic warfarin billed at a brand-tier copay instead of the Tier 1 generic price.
• Manufacturer coupon or savings card applied for a patient who has Medicare or Medicaid, which is prohibited and can result in a claim clawback later.
• Routine PT/INR blood test billed with a patient copay or applied to the Part B deductible when it should be a $0 covered clinical diagnostic laboratory service.
• Step therapy denial requiring a warfarin trial without documenting that warfarin is clinically inappropriate or was already tried and failed.
• Charged the standard copay after you already hit the $2,100 Part D annual out-of-pocket cap for the year across all your combined Part D drugs.

Frequently Asked Questions